Table 1: Clinical Trials for breast cancer treatment using oncolytic virotherapy.
| ID | Ststus | Phase | Actual enrolment | Type of disease | Virus | Additional Theraphy |
|---|---|---|---|---|---|---|
| NCT00574977 | completed | I | 26 | BC, Melanoma, HNSCC, LC, CRC, PanA | vvDD-CDSR (VV) | none |
| NCT00636558 | completed | I | 8 | BC, Melanoma, PC | CVA21 (Coxsackievirus) | none |
| NCT01017185 | completed | I | 28 | BC, refractory HNSCC, Skin, melanoma | HF10 (HSV) | none |
| NCT01656538 | completed | II | 81 | MBC | Reolysin (Reovirus) | Paclitaxel |
| NCT01846091 | active, not recruiting | I | 12 | ER-, ER+, HNSCC, HER2/Neu-, HER2/Neu+, MBC, PR+, PR-, Stage IV BC, TNBC | MV-NIS (MV) | none |
| NCT02285816 | recruiting | I/II | 56 | MBC, NSCLC, Esophageal and Gastric Cancer | MG1MA3 (oncolytic Maraba) and AdMA3 (AD vaccine) | none |
| NCT02630368 | recruiting | I/II | 118 | MBC, Advance Tissue Sarcoma | Jx-594 (oVV) | metronomic cyclophosphamide |
| NCT02779855 | active, not recruiting | I/II | 50 | Ductal BC, Ductal Carcinoma | Talimogene Laherparepvec (oHSV) | Paclitaxel (neoadjuvant) |
| NCT02977156 | recruiting | I | 66 | TNBC, Mesothelioma, HNSCC, CRC | Pexa-Vec (oVV) | lpilimumab |
| NCT03004183 | recruiting | II | 57 | TNBC, NSCLC | ADV/HSV-tk (oAd) | Pembrolizumab, stereotactic XRT |
| NCT03564782 | recruiting | I | 6 | Stage II-IV TNBC | PVSRIPO (oncolytic poliovirus) | none |
Abbreviations: Ad: Adenovirus; HSV: Herpes Simplex virus; MV: Measles Virus; VV: Vaccinia Virus; MV-NIS (MV): Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter; TNBC: Triple Negative Breast Cancer; MBC: Metastatic Breast Cancer; HNSCC: Head neck Squamous Cell Carcinoma; LC: Liver Carcinoma; CRC: Colorectal Cancer; PanA: Pancreatic Cancer; PC: Prostate Cancer; ER: Estrogen Receptor; PR: Progesterone Receptor; NSCLC: Non Small Cell Lung Cancer.